Eli Lilly Q2 Adjusted EPS $2.11 Beats $1.99 Estimate, Sales $8.31B Beat $7.58B Estimate
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly reported Q2 earnings of $2.11 per share, beating the analyst consensus estimate of $1.99 by 6.03%. This is a 68.8% increase from the same period last year. The company also reported quarterly sales of $8.31 billion, beating the analyst consensus estimate of $7.58 billion by 9.66%. This is a 28.11% increase from the same period last year.
August 08, 2023 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Q2 earnings and sales beat analyst estimates, showing significant YoY growth. This could positively impact the company's stock.
Eli Lilly's Q2 earnings and sales exceeded analyst estimates, which is typically a positive signal for investors. The significant YoY growth in both earnings and sales also indicates strong performance, which could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100